ID   PC-9/WZR10
AC   CVCL_DG31
SY   WZR10
DR   cancercelllines; CVCL_DG31
DR   GEO; GSM925740
DR   Progenetix; CVCL_DG31
DR   Wikidata; Q54938506
RX   PubMed=22961667;
CC   Population: Chinese; Han and Japanese.
CC   Selected for resistance to: ChEBI; CHEBI_49668; Gefitinib (ZD1839; Iressa).
CC   Selected for resistance to: ChEBI; CHEBI_61400; WZ4002 (N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide).
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_DH34 ! PC-9/GR4
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 19-12-24; Version: 15
//
RX   PubMed=22961667; DOI=10.1158/2159-8290.CD-12-0103; PMCID=PMC3477553;
RA   Ercan D., Xu C.-X., Yanagita M., Monast C.S., Pratilas C.A., Montero J.,
RA   Butaney M., Shimamura T., Sholl L.M., Ivanova E.V., Tadi M., Rogers A.,
RA   Repellin C., Capelletti M., Maertens O., Goetz E.M., Letai A.G.,
RA   Garraway L.A., Lazzara M.J., Rosen N., Gray N.S., Wong K.-K.,
RA   Janne P.A.;
RT   "Reactivation of ERK signaling causes resistance to EGFR kinase
RT   inhibitors.";
RL   Cancer Discov. 2:934-947(2012).
//